Faculty of Medicine, University of Alexandria
Alexandria, 00203, Egypt
NCT Number: NCT01425827
Osteoarthritis (OA), a common disabling condition, is the commonest type of arthritis worldwide.Pain is the leading symptom and is often chronic in na. Current treatment options have had limited symptomatic effect and are associated with significant side effects. Duloxetine, a selective serotonin norepinephrine reuptake inhibitor has been demonstrated to have, besides its antidepressant properties, a centrally acting analgesic effect.
The aim of the present study was to investigate the efficacy of duloxetine in reducing pain in older adults with knee OA.
288 patients aged 65 years and above with ACR clinical and radiographic criteria of primary knee OA attending the outpatient clinic of our institution were enrolled in this study. All patients underwent a physical examination and where questioned about the number of flares. Exclusion criteria included any inflammatory, autoimmune, psychiatric illness and morbid obesity. Patients were randomized 1:1. One hundred and forty four received 60mg/day of duloxetine HCL and 144 received placebo together with their usual therapy for 16 weeks. The primary outcome measure was pain reduction. Secondary outcome measures included improvements in physical functioning scores. Pain was assessed using the Brief Pain Inventory (BPI) and Visual Analogue pain Scale, (VAS, 0-100 mm). Functional assessment using the self-reported physical function as measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), WOMAC pain and stiffness scores and the Geriatric Depression Scale (GDS) was conducted. Alterations in dosage of analgesic/NSAID drugs used were recorded. Safety and tolerability were also assessed. Data was collected at baseline and at monthly intervals for 4 months. All staff involved in data collection was blinded to the treatment assignment groups.
Looking for future studies?
Notify Me50 year–85 year
All sexes
Interventional
Not applicable
Alexandria, 00203, Egypt
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
60 mg/day duloxetine for 16 weeks
similar looking tablets to the active agent for 16 weeks
Time frame: 16 weeks
University of Alexandria
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04326894
Arthritis, Inflammation
Alexandria, Egypt
View Trial DetailsNCT01907919
Bacterial De-contamination, Bio-stimulation
View Trial DetailsNCT07558720
Pain Reduction, We Are Not Studying a Disease or Condition
Karachi, Sindh, Pakistan
View Trial DetailsNCT07710404
Arthritis, Joint Diseases
Faisalābad, Punjab Province, Pakistan
View Trial Details